Ascentage Pharma announced on June 9, 2025, that 13 studies of its core assets, including olverembatinib (HQP1351), lisaftoclax (APG-2575), and APG-5918, were selected for presentation at the 2025 European Hematology Association (EHA) Annual Congress.
The presentations, scheduled for June 12-15, 2025, in Milan, Italy, will include an oral presentation on genomic and transcriptomic insights for predicting responses in CML patients receiving third-generation TKI therapy. Multiple poster presentations and online publications are also planned.
This extensive representation at EHA highlights Ascentage Pharma's robust pipeline and its commitment to advancing hematology research. The congress is a key platform for showcasing cutting-edge research and clinical results in the field.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.